Blog
RSS FeedPosted by Michael Wonder on 24 Feb 2021
Takeda’s drug for acute hereditary angioedema seizure to get larger benefits
24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for ...
Posted by Michael Wonder on 24 Feb 2021
Anti-cancer drugs Ninlaro, Lutathera to get insurance benefits from March
24 February 2021 - Takeda’s multiple myeloma treatment Ninlaro (ixazomib) and Novartis’ neuroendocrine tumour drug Lutathera (lutetium oxodotreotide) will get ...
Posted by Michael Wonder on 03 Feb 2021
Parkinson’s disease drug Equifina gets insurance benefits
1 February 2021 - The government has decided to grant health insurance benefits to Eisai’s Parkinson’s disease treatment, Equifina (safinamide), ...
Posted by Michael Wonder on 19 Jan 2021
Regulators OK Yuhan's Leclaza as 31st novel drug
18 January 2020 - Yuhan said Monday that it has received sales approval for Leclaza (lazertinib), a drug targeting epidermal ...
Posted by Michael Wonder on 12 Jan 2021
Janssen's ulcerative colitis treatment to receive reimbursement
12 January 2021 - Janssen Pharmaceutical said Tuesday that the Ministry of Health and Welfare would begin to reimburse Stelara, ...
Posted by Michael Wonder on 30 Dec 2020
Tiered drug pricing policy widens price difference among generic drugs
30 December 2020 - In July, the nation implemented a “tiered system” to restructure the drug-pricing method, which called for ...
Posted by Michael Wonder on 22 Oct 2020
Will HIRA resume talk to grant benefits for anti-diabetic combo drugs?
22 October 2020 - Three makers of SGLT-2 inhibiting anti-diabetic drugs said they would seek changes in approval conditions to ...
Posted by Michael Wonder on 13 Oct 2020
Daewoong's antipyretic unable to get insurance benefits
13 October 2020 - Daewoong Pharmaceutical has failed to list Fiblast (trafermin), a burn treatment drug developed by Japan's Kaken ...
Posted by Michael Wonder on 14 Sep 2020
Will Tagrisso win insurance benefits in Korea, too?
14 September 2020 - AstraZeneca’s Tagrisso, targeted therapy for lung cancer, has won recognition as the first-line standard treatment for ...
Posted by Michael Wonder on 31 Aug 2020
‘Korea should introduce indication-specific drug pricing’
31 August 2020 - “Korea must introduce a system to apply different prices for a drug’s multiple indications, to guarantee ...
Posted by Michael Wonder on 27 Aug 2020
Drug makers to sue government for limiting choline alfoscerate benefit
27 August 2020 - Manufacturers of choline alfoscerate, a dementia drug, are reportedly preparing to file an administrative lawsuit against ...
Posted by Michael Wonder on 12 Aug 2020
Takeda expects more effective IBD treatment with Kynteles' expanded reimbursement
12 August 2020 - Takeda Korea is strengthening its position in the domestic inflammatory bowel disease market with Kynteles receiving ...
Posted by Michael Wonder on 11 Aug 2020
Petitioner demands insurance benefit for breast cancer drug Kadcyla
11 August 2020 - A woman has requested that the government grant reimbursement for using Kadcyla of Roche in treating ...
Posted by Michael Wonder on 07 Aug 2020
Rheumatoid arthritis drug Rinvoq gets insurance benefit
7 August 2020 - AbbVie Korea’s rheumatoid arthritis treatment Rinvoq (upadacitinib) has obtained the national health insurance benefit. ...
Posted by Michael Wonder on 03 Aug 2020
ISPOR announces Virtual ISPOR Asia Pacific 2020
3 August 2020 - ISPOR—The Professional Society for Health Economics and Outcomes Research announced its Virtual ISPOR Asia Pacific 2020 ...